New cyclometallated Ru(ii) complex for potential application in photochemotherapy?

Albani, Bryan A.; Peña, Bruno; Dunbar, Kim R.; Turró, Claudia

doi:10.1039/c3pp50327e

Cited by 52 publications

(55 citation statements)

References 56 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…5). A similar trend was reported for the photochemically inert complex [Ru(biq) 2 (phpy)] + (phpy À = deprotonated 2-phenylpyridine), which emits at 980 nm in CH 3 CN at 77 K (47). It should also be noted that the shorter excited state lifetime in 2 compared to 1 is consistent with the lower energy of the emissive state in the former relative to the latter, as predicted by the energy gap law (49,50).…”

Section: Photochemistrysupporting

confidence: 81%

“…The quantum yields for the dpb ligand exchange in 1 were measured to be Φ 550 = 0.015(4) and Φ 600 = 0.0094(8) in H 2 O; these values are slightly lower than those reported for 4 under similar conditions, Φ 550 = 0.020(3) and Φ 600 = 0.024(2) . The lower quantum yields for 1 can be attributed to the poor solubility of the dpb ligand relative to the biq ligand in H 2 O, which would make the escape from the solvent cage less favorable for the former and its subsequent recombination to regenerate 1 more likely.…”

Section: Resultsmentioning

confidence: 83%

See 1 more Smart Citation

Steric and Electronic Factors Associated with the Photoinduced Ligand Exchange of Bidentate Ligands Coordinated to Ru(II)

Albani

Whittemore

Durr

et al. 2014

Photochem & Photobiology

Self Cite

View full text Add to dashboard Cite

In an effort to create a molecule that can absorb low energy visible or near-infrared light for photochemotherapy (PCT), the new complexes [Ru(biq)2 (dpb)](PF6 )2 (1, biq = 2,2'-biquinoline, dpb = 2,3-bis(2-pyridyl)benzoquinoxaline) and [(biq)2 Ru(dpb)Re(CO)3 Cl](PF6 )2 (2) were synthesized and characterized. Complexes 1 and 2 were compared to [Ru(bpy)2 (dpb)](PF6 )2 (3, bpy = 2,2'-bipyridine) and [Ru(biq)2 (phen)](PF6 )2 (4, phen = 1,10-phenanthroline). Distortions around the metal and biq ligands were used to explain the exchange of one biq ligand in 4 upon irradiation. Complex 1, however, undergoes photoinduced dissociation of the dpb ligand rather than biq under analogous experimental conditions. Complex 3 is not photoactive, providing evidence that the biq ligands are crucial for ligand photodissociation in 1. The crystal structures of 1 and 4 are compared to explain the difference in photochemistry between the complexes. Complex 2 absorbs lower energy light than 1, but is photochemically inert although its crystal structure displays significant distortions. These results indicate that both the excited state electronic structure and steric bulk play key roles in bidentate photoinduced ligand dissociation. The present work also shows that it is possible to stabilize sterically hindered Ru(II) complexes by the addition of another metal, a property that may be useful for other applications.

show abstract

Section: Photochemistrysupporting

confidence: 81%

Section: Resultsmentioning

confidence: 83%

Steric and Electronic Factors Associated with the Photoinduced Ligand Exchange of Bidentate Ligands Coordinated to Ru(II)

Albani

Whittemore

Durr

et al. 2014

Photochem & Photobiology

Self Cite

View full text Add to dashboard Cite

show abstract

“…Such bathochromic absorption is in agreement with the extremely low reduction potentials measured by cyclic voltammetry. It should be noted that ruthenium(II) complexes absorbing red light are rare, and have scarcely been reported in the literature …”

Section: Resultsmentioning

confidence: 99%

New Ruthenium‐Based Probes for Selective G‐Quadruplex Targeting

Piraux

Bar

Abraham

et al. 2017

Chemistry A European J

View full text Add to dashboard Cite

Telomeric regions containing G-quadruplex (G4) structures play a pivotal role in the development of cancers. The development of specific binders for G4s is thus of great interest in order to gain a deeper understanding of the role of these structures, and to ultimately develop new anticancer drug candidates. For several years, Ru complexes have been studied as efficient probes for DNA. Interest in these complexes stems mainly from the tunability of their structures and properties, and the possibility of using light excitation as a tool to probe their environment or to selectively trigger their reaction with a biological target. Herein, we report on the synthesis and thorough study of new Ru complexes based on a novel dipyrazino[2,3-a:2',3'-h]phenazine ligand (dph), obtained through a Chichibabin-like reaction. Luminescence experiments, surface plasmon resonance (SPR), and computational studies have demonstrated that these complexes behave as selective probes for G-quadruplex structures.

show abstract

“…reported that 13p is not an optimal compound for PDT due to its high cytotoxicity in the dark and its lack of photochemical sensitivity. 230 They found a 7-fold increase in the cytotoxicity of cycloruthenated complex 13p upon irradiation with light at 639 nm.…”

Section: Ruthenium(ii) Polypyridyl Complexesmentioning

confidence: 98%

The development of anticancer ruthenium(ii) complexes: from single molecule compounds to nanomaterials

et al. 2017

View full text Add to dashboard Cite

Cancer is rapidly becoming the top killer in the world. Most of the FDA approved anticancer drugs are organic molecules, while metallodrugs are very scarce. The advent of first metal based therapeutic agent, cisplatin, launched a new era in the application of transition metal complexes for therapeutic design. Due to their unique and versatile biochemical properties, ruthenium-based compounds have emerged as promising anti-cancer agents that serve as alternatives to cisplatin and its derivertives. The ruthenium(III) complexes have successfully been used in clinical research and their mechanisms of anticancer action have been reported in large volumes over the past few decades. Ruthenium(II) complexes have also attracted significant attention as anticancer candidates; however, only few of them have been reported comprehensively. In this review, we discuss the development of ruthenium(II) complexes as anticancer candidates and biocatalysts, including arene ruthenium complexes, polypyridyl ruthenium complexes, and ruthenium nanomaterial complexes. This review focuses on the likely mechanisms of action of ruthenium(II)-based anticancer drugs and the relationship between their chemical structures and biological properties. This review also highlights the catalytic activity and the photoinduced activation of ruthenium(II) complexes, their targeted delivery, and their activity in nanomaterial systems.

show abstract

New cyclometallated Ru(ii) complex for potential application in photochemotherapy?

Cited by 52 publications

References 56 publications

Steric and Electronic Factors Associated with the Photoinduced Ligand Exchange of Bidentate Ligands Coordinated to Ru(II)

Steric and Electronic Factors Associated with the Photoinduced Ligand Exchange of Bidentate Ligands Coordinated to Ru(II)

New Ruthenium‐Based Probes for Selective G‐Quadruplex Targeting

The development of anticancer ruthenium(ii) complexes: from single molecule compounds to nanomaterials

Contact Info

Product

Resources

About